Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 577Carcinoma, Non-Small-Cell Lung 491Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 121Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 77Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Primary Breast Cancer × Paclitaxel × Clear all
NCT01019616 2021-11-29

Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy

Peking University

Phase 3 Unknown
400 enrolled
Breast

Primary Breast Cancer

NCT04127019 2020-02-26

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Fudan University

Phase 3 Completed
2,079 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡